What is TTRX's stock issuance proceeds?

TTRX (TTRX) reported stock issuance proceeds of $100K in Q4 2025.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

TTRX TTRX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron PharmaceuticalsREGN

$163.1M+169%

Journey Medical CorporationDERM

$72K-98.2%

Celldex TherapeuticsCLDX

$327K+61.9%

Arcutis Biotherapeutics, Inc.ARQT

$1.07M—

Kymera TherapeuticsKYMR

$19.19M—

PVL

Palvella TherapeuticsPVLA

$230M—

Other financials

Income statement

See full

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

See full

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

See full

Operating cash flow-$1.6M-448%

Valuation

See full

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

See full

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: TTRX’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TTRX's stock issuance proceeds?: TTRX (TTRX) reported stock issuance proceeds of $100K in Q4 2025.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.